Lilly-backed Superluminal raises $120M series A to bring membrane receptor drugs into the clinic

Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by the likes of Eli Lilly.